Syros Pharmaceuticals Inc (SYRS) Shares Bought by Rhumbline Advisers

Rhumbline Advisers lifted its holdings in Syros Pharmaceuticals Inc (NASDAQ:SYRS) by 87.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,472 shares of the company’s stock after buying an additional 10,494 shares during the quarter. Rhumbline Advisers’ holdings in Syros Pharmaceuticals were worth $229,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Redmile Group LLC raised its holdings in shares of Syros Pharmaceuticals by 159.3% in the first quarter. Redmile Group LLC now owns 1,652,240 shares of the company’s stock valued at $21,446,000 after buying an additional 1,015,008 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Syros Pharmaceuticals by 61.7% in the first quarter. BlackRock Inc. now owns 929,537 shares of the company’s stock valued at $12,066,000 after buying an additional 354,591 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Syros Pharmaceuticals by 13.9% in the first quarter. JPMorgan Chase & Co. now owns 374,513 shares of the company’s stock valued at $4,861,000 after buying an additional 45,715 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Syros Pharmaceuticals by 35.0% in the first quarter. Northern Trust Corp now owns 181,090 shares of the company’s stock valued at $2,351,000 after buying an additional 46,927 shares during the last quarter. Finally, Millennium Management LLC bought a new position in shares of Syros Pharmaceuticals in the first quarter valued at about $2,126,000. 60.70% of the stock is owned by institutional investors and hedge funds.

Several brokerages have weighed in on SYRS. ValuEngine raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 6th. Zacks Investment Research cut Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 17th. Cowen reissued a “buy” rating on shares of Syros Pharmaceuticals in a report on Tuesday, July 17th. BidaskClub raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 31st. Finally, HC Wainwright reissued a “hold” rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a report on Wednesday, August 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $21.00.

Shares of NASDAQ:SYRS opened at $12.67 on Tuesday. The stock has a market cap of $434.82 million, a price-to-earnings ratio of -5.95 and a beta of -2.06. Syros Pharmaceuticals Inc has a 1-year low of $6.30 and a 1-year high of $17.62.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Friday, August 10th. The company reported ($0.43) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.07. The firm had revenue of $0.38 million for the quarter, compared to the consensus estimate of $1.33 million. equities analysts anticipate that Syros Pharmaceuticals Inc will post -1.85 earnings per share for the current fiscal year.

Syros Pharmaceuticals Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Further Reading: Stock Symbol

Want to see what other hedge funds are holding SYRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syros Pharmaceuticals Inc (NASDAQ:SYRS).

Institutional Ownership by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply